Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting · New long-term data presented at AES 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback